Acetylcholinesterase inhibitors as a starting point towards improved Alzheimer's disease therapeutics

Current Pharmaceutical Design

Volumn 10, Issue 25, 2004, Pages 3157-3166

  Recanatini, Maurizio ^a   Valenti, Piero ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Alzheimer's disease; Amyloid ; Cholinesterase inhibitors; Drug design; Molecular modelling; Neurodegeneration

Indexed keywords

3 CHLORO 7 HYDROXY 4 METHYLCOUMARIN; 4,4' BIPYRIDINE; ACETYLCHOLINESTERASE; AMBENONIUM; AMYLOID BETA PROTEIN; AP 1716; AP 2238; BENZYLINDENOQUINOLINYLAMINE; CAPROCTAMINE; CARBAMIC ACID DERIVATIVE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; COUMARIN DERIVATIVE; DECAMETHONIUM; DITACRINE; DONEPEZIL; ENZYME INHIBITOR; GALANTAMINE; NEUROTRANSMITTER; NOOTROPIC AGENT; PHENYL N N BUTYLCARBAMATE; PROPIDIUM IODIDE; QUINOLINE DERIVATIVE; RIVASTIGMINE; TACRINE; TACRINE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CHOLINERGIC TRANSMISSION; DRUG DESIGN; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; HYPOTHESIS; NERVE DEGENERATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; THEORY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BRAIN; CHOLINESTERASE INHIBITORS; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE;

EID: 4544236922     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383313     Document Type: Review

References (68)

1. Bartus RT, Dean RL III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408-14.
2. Bartus RT. On neurodegencrative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 2000; 163: 495-529.
3. Gualtieri F, Dei S, Manetti D, Romanelli MN, Scapecchi S, Teodori E. The medicinal chemistry of Alzheimer's and Alzheimer-like diseases with emphasis on the cholinergic hypothesis. Farmaco 1995; 50: 489-503.
4. Camps P, Muñoz-Torrero D. Cholinergic drugs in pharmacotherapy of Alzheimer's disease. Mini Rev Med Chem 2002; 2: 11-25.
5. Messer WS, Jr. Cholinergic agonists and the treatment of Alzheimer's disease. Curr Top Med Chem 2002, 2: 353-8.
6. Moghul S, Wilkinson D. Use of acetylcholinesterase inhibitors in Alzheimer's disease. Expert Rev Neurotherapeutics 2001; 1: 61-9.
7. Recanatini M, Cavalli A. Acetylcholinesterase inhibitors in the context of therapeutic strategies to combat Alzheimer's disease. Expert Opin Ther Pat 2002; 12: 1853-65.
8. Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann NY Acad Sci 2000; 924: 17-25.
9. Butterfield DA, Drake J, Pocernich C, Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med 2001; 7: 548-54.
10. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-6.
11. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci 2003; 4: 49-60.
12. Dominguez DI, De Strooper B. Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease. Trends Pharmacol Sci 2002; 23: 324-30.
13. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992; 258: 304-7.
14. Roberson MR, Harrell LE. Cholinergic activity and amyloid precursor protein metabolism. Brain Res Rev 1997; 25: 50-69.
15. Rossner S, Ueberham U, Schliebs R, Perez-Polo JR, Bigl V. The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. Prog Neurobiol 1998; 56: 541-69.
16. Nitsch RM, Deng M, Tennis M, Schoenfeld D, Growdon JH. The selective muscarinic M1 agonist AF102B decreases levels of total Aβ in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 2000; 48: 913-8.
17. Hock C, Maddalena A, Heuser I, Naber D, Oertel W, von der Kammer H, et al. Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospinal fluid levels of total amyloid beta-peptide in patients with Alzheimer's disease. Ann NY Acad Sci 2000; 920: 285-91.
18. Hock C, Maddalena A, Raschig A, Muller-Spahn F, Eschweiler G, Hager K, et al. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of Aβ42 in patients with Alzheimer's disease. Amyloid 2003; 10: 1-6.
19. Alvarez A, Bronfman F, Perez CA, Vicente M, Garrido J, Inestrosa NC. Acetylcholinesterase, a senile plaque component, affects the fibrillogenesis of amyloid-β-peptides. Neurosci Lett 1995; 201: 49-52.
20. Alvarez A, Opazo C, Alarcon R, Garrido J, Inestrosa NC. Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. J Mol Biol 1997; 272: 348-61.
21. De Ferrari GV, Canales MA, Shin I, Weiner LM, Silman I, Inestrosa NC. A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. Biochemistry 2001; 40: 10447-57.
22. Inestrosa NC, Alvarez A, Perez CA, Moreno RD, Vicente M, Linker C, et al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site ofthe enzyme. Neuron 1996; 16: 881-91.
23. Doraiswamy PM, Steffens DC. Combination therapy for early Alzheimer's disease: what are we waiting for? J Am Geriatr Soc 1998; 46: 1322-4.
24. Giacobini E. In: Giacobini E Ed. Cholinesterases and cholinesterase inhibitors. London, Martin Dunitz Ltd. 2000; 181-226.
25. McKenna MT, Proctor GR, Young LC, Harvey AL. Novel tacrine analogues for potential use against Alzheimer's disease: potent and selective acetylcholinesterase inhibitors and 5-HT uptake inhibitors. J Med Chem 1997; 40: 3516-23.
26. Melchiorre C, Andrisano V, Bolognesi ML, Budriesi R, Cavalli A, Cavrini V, el al. Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease. J Med Chem 1998; 41: 4186-9.
27. Martinez A, Fernandez E, Castro A, Conde S, Rodriguez-Franco I, Baños JE, et al. N-Benzylpiperidine derivatives of 1, 2, 4-thiadiazolidinone as new acetylcholinesterase inhibitors. Eur J Med Chem 2000; 35: 913-22.
28. Bruhlmann C, Ooms F, Carrupt PA, Testa B, Catto M, Leonetti F, et al. Coumarins derivatives as dual inhibitors of acetylcholinesterase and monoamine oxidase. J Med Chem 2001; 44: 3195-8.
29. Nakamura S, Kawashima S, Nakano S, Tsuji T, Araki W. Subcellular distribution of acetylcholinesterase in Alzheimer's disease: abnormal localisation and solubilisation. J Neural Transm Suppl 1990; 30: 13-23.
30. Ulrich J, Meier-Ruge W, Probst A, Meier E, Ipsen S. Senile plaques: staining for acetylcholinesterase and A4 protein: a comparative study in the hippocampus and entorhinal cortex. Acta Neuropathol (Berl) 1990; 80: 624-8.
31. Alvarez A, Alarcon R, Opazo C, Campos EC, Munoz FJ, Calderon FH, et al. Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. J Neurosci 1998; 18: 3213-23.
32. Reyes AE, Perez DR, Alvarez A, Garrido J, Gentry MK, Doctor BP, et al. A monoclonal antibody against acetylcholinesterase inhibits the formation of amyloid fibrils induced by the enzyme. Biochem Biophys Res Commun 1997; 232: 652-5.
33. Rees T, Hammond PI, Soreq H, Younkin S, Brimijoin S. Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. Neurobiol Aging 2003; 24: 777-87.
34. Soreq H, Seidman S. Acetylcholinesterase-new roles for an old actor. Nat Rev Neurosci 2001; 2: 294-302.
35. Ordentlich A, Barak D, Kronman C, Flashner Y, Leitner M, Segall Y, et al. Dissection of the human acetylcholinesterase active center determinants of substrate specificity. Identification of residues constituting the anionic site, the hydrophobic site, and the acyl pocket. J Biol Chem 1993; 268: 17083-95.
36. Barak D, Kronman C, Ordentlich A, Ariel N, Bromberg A, Marcus D, et al. Acetylcholinesterase peripheral anionic site degeneracy conferred by amino acid arrays sharing a common core. J Biol Chem 1994; 269: 6296-305.
37. Bourne Y, Taylor P, Bougis PE, Marchot P. Crystal structure of mouse acetylcholinesterase. A peripheral site-occluding loop in a tetrameric assembly. J Biol Chem 1999; 274: 2963-70.
38. Castro A, Martinez A. Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease. Mini Rev Med Chem 2001; 1: 267-72.
39. Taylor P, Lappi S. Interaction of fluorescence probes with acetylcholinesterase. The site and specificity of propidium binding. Biochemistry 1975; 14: 1989-97.
40. Radic Z, Reiner E, Taylor P. Role of the peripheral anionic site on acetylcholinesterase: inhibition by substrates and coumarin derivatives. Mol Pharmacol 1991; 39: 98-104.
41. Harel M, Schalk I, Ehret-Sabatier L, Bonet F, Goeldner M, Hirth C, et al. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc Natl Acad Sci USA 1993; 90: 9031-5.
42. Hodge AS, Humphrey DR, Rosenberry TL. Ambenonium is a rapidly reversible noncovalent inhibitor of acetylcholinesterase, with one of the highest known affinities. Mol Pharmacol 1992; 41: 937-42.
43. Krupka RM. Acetylcholinesterase: trimethylammonium-ion inhibition of deacetylation. Biochemistry 1964; 3: 1749-54.
44. Sussman JL, Harel M, Silman I. Three-dimensional structure of acetylcholinesterase and of its complexes with anticholinesterase drugs. Chem Biol Interact 1993; 87: 187-97.
45. Rampa A, Bisi A, Belluti F, Gobbi S, Valenti P, Andrisano V, et al. Acetylcholinesterase inhibitors for potential use in Alzheimer's disease: molecular modeling, synthesis and kinetic evaluation of 11H-indeno-[1, 2-b]-quinolin-10-ylamine derivatives. Bioorg Med Chem 2000; 8: 497-506.
46. Kryger G, Silman I, Sussman JL. Three-dimensional structure of a complex of E2020 with acetylcholinesterase from Torpedo californica. J Physiol Paris 1998; 92: 191-4.
47. Pang YP, Quiram P, Jelacic T, Hong F, Brimijoin S. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease. J Biol Chem 1996; 271: 23646-9.
48. Bartolini M, Bertucci C, Cavrini V, Andrisano V. Beta-amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem Pharmacol 2003; 65: 407-16.
49. Harel M, Kleywegt GJ, Ravelli RB, Silman I, Sussman JL. Crystal structure of an acetylcholinesterase-fasciculin complex: interaction of a three-fingered toxin from snake venom with its target. Structure 1995; 3: 1355-66.
50. Lin G, Tsai YC, Liu HC, Liao WC, Chang CH. Enantiomeric inhibitors of cholesterol esterase and acetylcholinesterase. Biochim Biophys Acta 1998; 1388: 161-74.
51. Lin G, Lai CY, Liao WC. Molecular recognition by acetylcholinesterase at the peripheral anionic site: structure-activity relationships for inhibitions by aryl carbamates. Bioorg Med Chem 1999; 7: 2683-9.
52. Reiner E, Radic Z. In: Giacobini E Ed, Cholinesterases and cholinesterase inhibitors. London, Martin Dunitz Ltd. 2000; 103-19.
53. Simeon-Rudolf V. Kovarik Z, Radic Z, Reiner E. Reversible inhibition of acetylcholinesterase and butyrylcholinesterase by 4, 4′-bipyridine and by a coumarin derivative. Chem Biol Interact 1999; 119-120: 119-28.
54. Carlier PR, Chow ES, Han Y, Liu J, El Yazal J, Pang YP. Heterodimeric tacrine-based acetylcholinesterase inhibitors: investigating ligand-peripheral site interactions. J Med Chem 1999; 42: 4225-31.
55. Carlier PR, Han YF, Chow ES, Li CP, Wang H, Lieu TX, et al. Evaluation of short-tether bis-THA AChE inhibitors. A further test of the dual binding site hypothesis. Bioorg Med Chem 1999; 7: 351-7.
56. Han YF, Li CP, Chow E, Wang H, Pang YP, Carlier PR. Dual-site binding of bivalent 4-aminopyridine- and 4-aminoquinoline-based AChE inhibitors: contribution of the hydrophobic alkylene tether to monomer and dimer affinities. Bioorg Med Chem 1999; 7: 2569-75.
57. Lewis WG, Green LG, Grynszpan F, Radic Z, Carlier PR, Taylor P, et al. Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. Angew Chem Int Ed Engl 2002; 41: 1053-7.
58. Savini L, Gaeta A, Fattorusso C, Catalanotti B, Campiani G, Chiasserini L, et al. Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors. J Med Chem 2003; 46: 1-4.
59. Tumiatti V, Rosini M, Bartolini M, Cavalli A, Marucci G, Andrisano V, et al. Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 2. Role of the substituents on the phenyl ring and nitrogen atoms of caproctamine. J Med Chem 2003; 46: 954-66.
60. Bartolini M, Bertucci C, Gotti R, Tumiatti V, Cavalli A, Recanatini M, et al. Determination of the dissociation constants (pKa) of basic acetylcholinesterase inhibitors by reversed-phase liquid chromatography. J Chromatogr A 2002; 958: 59-67.
61. Valenti P, Rampa A, Bisi A, Fabbri G, Andrisano V, Cavrini V. Cholinergic agents. Synthesis and acety1cholinesterase inhibitory activity of some ω-[N-methyl-N-(3-alkylcarbamoyloxyphenyl -methyl]aminoalkoxyxanthen-9-ones. Med Chem Res 1995; 5: 255-64.
62. Rampa A, Bisi A, Valenti P, Recanatini M, Cavalli A, Andrisano V, et al. Acetylcholinesterase inhibitors: synthesis and structure-activity relationships of ω-[N-methyl-N-(3-alkylcarbamoyloxy-phenyl -methyl]aminoalkoxyheteroaryl derivatives. J Med Chem 1998; 41: 3976-86.
63. Rampa A, Piazzi L, Belluti F, Gobbi S, Bisi A, Bartolini M, et al. Acetylcholinesterase inhibitors: SAR and kinetic studies on ω-[N-methyl-N-(3-alkylcarbamoyloxyplienyl)niethyl]aminoalkoxyaryl derivatives. J Med Chem 2001; 44: 3810-20.
64. Belluti F, Piazzi L, Rampa A, Gobbi S, Bisi A, Bartolini M, et al. In XVI Convegno Nazionale, Divisione di Chimica Farmaceutica della Società Chimica Italiana: Sorrento (Italy), September 18-22, 2002.
65. Piazzi L, Rampa A, Bisi A, Gobbi S, Belluti F, Cavalli A, et al. 3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6, 7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. J Med Chem 2003; 46: 2279-82.
66. Conway KA, Baxter EW, Felsenstein KM, Reitz AB. Emerging beta-amyloid therapies for the treatment of Alzheimer's disease. Curr Pharm Design 2003; 9(6): 427-47.
67. Pharm Design 2003; 9(6): 449-54.
68. van Drie JH. Pharmacophore discovery - lessons learned. Curr Pharm Design 2003; 9(20): 1649-64.